3SBio stock fell 4.35 percent as interim profit declinedante

Published on 10/04/2026 at 19:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

3SBio stock reported RMB 4.53 billion in revenue for the six months ended June 30, 2026. Adjusted operating net profit rose 26.5 percent to RMB 1.44 billion.

3SBio, KYG8875G1029, Illustration mit AI erstellt.

3SBio (ISIN KYG8875G1029) stock closed at HKD 15.85 on the Hong Kong Stock Exchange on October 2, 2026, down 4.35 percent from the prior close of HKD 16.57. The move followed interim figures showing higher revenue but lower reported profit, while adjusted operating earnings improved.

Revenue grew but profit fell

According to Futu on September 30, 2026, 3SBio reported revenue of RMB 4.53 billion for the six months ended June 30, 2026, up 3.9 percent year over year. Net profit attributable to equity shareholders fell 15.6 percent to RMB 1.15 billion, and basic earnings per share stood at RMB 0.45.

The earnings mix was uneven. Licensing income reached RMB 850 million, while CDMO revenue increased 160.9 percent to RMB 230 million; biological product sales declined 19.3 percent to RMB 3.44 billion in the same period, according to Futu.

Adjusted earnings add support

Adjusted operating net profit increased 26.5 percent to RMB 1.44 billion in the first half of 2026. Research and development spending rose 24.9 percent to RMB 680 million, or 15.1 percent of revenue, as the company advanced programs in oncology, autoimmune disease, nephrology, metabolism and dermatology, Futu reported.

The contrast between mature-product pressure and newer revenue streams is central to the results. Selling and distribution expenses decreased 25.3 percent to RMB 1.21 billion, while the gross margin declined from 85.3 percent to 83.8 percent in the six-month period.

Analysts see a wide valuation gap

Investing.com lists a Strong Buy consensus from 13 analysts as of October 4, 2026, with 12 Buy ratings, 1 Hold rating and 0 Sell ratings. The average 12-month price target is HKD 31.15, which lies 96.50 percent above the HKD 15.85 reference price.

That optimism rests against a clear counter-factor: the interim report identified medical insurance reforms, centralized procurement and value-added tax changes as pressures on traditional product sales. For investors, the key test is whether licensing income, CDMO expansion and newer products can offset that pressure.

3SBio stock stays below its yearly high

3SBio stock closed at HKD 15.85 on the Hong Kong Stock Exchange on October 2, 2026. The 52-week range was HKD 14.81 to HKD 35.42, and market capitalization stood at HKD 39.5 billion.